Interferon-alpha treatment rapidly clears Hepatitis e virus infection in humanized mice

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Van De Garde, Martijn D B ^a   Pas, Suzan D ^a   Van Oord, Gertine W ^a   Gama, Lucio ^c   Choi, Youkyung ^d   De Man, Robert A ^a   Boonstra, Andre ^a   Vanwolleghem, Thomas ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROGOL; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECT; HEPATITIS B VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOUSE; VIROLOGY; VIRUS LOAD; XENOGRAFT;

ANIMALS; ANTIVIRAL AGENTS; BIOMARKERS; CHEMOKINE CXCL10; DISEASE MODELS, ANIMAL; HEPATITIS B VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HETEROGRAFTS; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; MICE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; VIRAL LOAD;

EID: 85027523562     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07434-y     Document Type: Article

References (51)

1. Dalton, H. R., Seghatchian, J. Hepatitis E virus: Emerging from the shadows in developed countries. Transfusion and apheresis science: Official journal of the World Apheresis Association: Official journal of the European Society for Haemapheresis. doi: 10.1016/j.transci.2016.10.016 (2016).
2. Smith, D. B., et al. Consensus proposals for classification of the family Hepeviridae. The Journal of general virology 95, 2223-2232, doi: 10.1099/vir.0.068429-0 (2014).
3. Aggarwal, R., Jameel, S. Hepatitis E. Hepatology 54, 2218-2226, doi: 10.1002/hep.24674 (2011).
4. Khuroo, M. S., Kamili, S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. Journal of viral hepatitis 10, 61-69 (2003).
5. Krain, L. J., Nelson, K. E., Labrique, A. B. Host immune status and response to hepatitis E virus infection. Clinical microbiology reviews 27, 139-165, doi: 10.1128/CMR.00062-13 (2014).
6. Kamar, N., et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140, 1481-1489, doi: 10.1053/j.gastro.2011.02.050 (2011).
7. Pas, S. D., et al. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerging infectious diseases 18, 869-872, doi: 10.3201/eid1805.111712 (2012).
8. Nijskens, C. M., et al. Hepatitis E virus genotype 3 infection in a tertiary referral center in the Netherlands: Clinical relevance and impact on patient morbidity. Journal of clinical virology: The official publication of the Pan American Society for Clinical Virology 74, 82-87, doi: 10.1016/j.jcv.2015.11.038 (2016).
9. Kamar, N., et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. The New England journal of medicine 370, 1111-1120, doi: 10.1056/NEJMoa1215246 (2014).
10. Peters van Ton, A. M., Gevers, T. J., Drenth, J. P. Antiviral therapy in chronic hepatitis E: A systematic review. Journal of viral hepatitis 22, 965-973, doi: 10.1111/jvh.12403 (2015).
11. Alric, L., Bonnet, D., Laurent, G., Kamar, N., Izopet, J. Chronic hepatitis E virus infection: Successful virologic response to pegylated interferon-alpha therapy. Annals of internal medicine 153, 135-136, doi: 10.7326/0003-4819-153-2-201007200-00256 (2010).
12. Berto, A., et al. Replication of hepatitis E virus in three-dimensional cell culture. Journal of virological methods 187, 327-332, doi: 10.1016/j.jviromet.2012.10.017 (2013).
13. Nguyen, H. T., Shukla, P., Torian, U., Faulk, K., Emerson, S. U. Hepatitis E virus genotype 1 infection of swine kidney cells in vitro is inhibited at multiple levels. Journal of virology 88, 868-877, doi: 10.1128/JVI.02205-13 (2014).
14. Nguyen, H. T., et al. A naturally occurring human/hepatitis E recombinant virus predominates in serum but not in faeces of a chronic hepatitis E patient and has a growth advantage in cell culture. The Journal of general virology 93, 526-530, doi: 10.1099/vir.0.037259-0 (2012).
15. van de Garde, M. D., et al. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection. Journal of virology 90, 4394-4401, doi: 10.1128/JVI.00114-16 (2016).
16. Tanaka, T., Takahashi, M., Kusano, E., Okamoto, H. Development and evaluation of an efficient cell-culture system for Hepatitis E virus. The Journal of general virology 88, 903-911, doi: 10.1099/vir.0.82535-0 (2007).
17. Nair, V. P., et al. Endoplasmic Reticulum Stress Induced Synthesis of a Novel Viral Factor Mediates Efficient Replication of Genotype-1 Hepatitis E Virus. PLoS pathogens 12, e1005521, doi: 10.1371/journal.ppat.1005521 (2016).
18. Devhare, P. B., Desai, S., Lole, K. S. Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies. Scientific reports 6, 26827, doi: 10.1038/srep26827 (2016).
19. Todt, D., et al. Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrobial agents and chemotherapy 60, 2132-2139, doi: 10.1128/AAC.02427-15 (2016).
20. Zhou, X., et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of viral hepatitis 23, 294-304, doi: 10.1111/jvh.12491 (2016).
21. Dong, C., et al. Suppression of interferon-alpha signaling by hepatitis E virus. Hepatology 55, 1324-1332, doi: 10.1002/hep.25530 (2012).
22. Keskinen, P., et al. Impaired antiviral response in human hepatoma cells. Virology 263, 364-375, doi: 10.1006/viro.1999.9983 (1999).
23. Debing, Y., et al. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. Journal of hepatology 65, 499-508, doi: 10.1016/j.jhep.2016.05.002 (2016).
24. van der Valk, M., Zaaijer, H. L., Kater, A. P., Schinkel, J. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. Journal of hepatology. doi: 10.1016/j.jhep.2016.09.014 (2016).
25. Donnelly, M. C., et al. Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient. Gastroenterology. doi: 10.1053/j.gastro.2016.05.060 (2016).
26. Wang, W., et al. Distinct Antiviral Potency of Sofosbuvir Against Hepatitis C and E Viruses. Gastroenterology 151, 1251-1253, doi: 10.1053/j.gastro.2016.09.061 (2016).
27. Dao Thi, V. L., et al. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. Gastroenterology 150, 82-85 e84, doi: 10.1053/j.gastro.2015.09.011 (2016).
28. Sayed, I. M., et al. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. Gut. doi: 10.1136/gutjnl-2015-311109 (2016).
29. Allweiss, L., et al. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. Journal of hepatology 64, 1033-1040, doi: 10.1016/j.jhep.2016.01.011 (2016).
30. Chen, L., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444 (2005).
31. McGilvray, I., et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 142, 1122-1131 e1121, doi: 10.1053/j.gastro.2012.01.028 (2012).
32. Feld, J. J., et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46, 1548-1563, doi: 10.1002/hep.21853 (2007).
33. Allweiss, L., et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. Journal of hepatology 60, 500-507, doi: 10.1016/j.jhep.2013.10.021 (2014).
34. Kneteman, N. M., et al. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 43, 1346-1353, doi: 10.1002/hep.21209 (2006).
35. Watanabe, T., et al. Hepatitis C virus kinetics by administration of pegylated interferon-alpha in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut 62, 1340-1346, doi: 10.1136/gutjnl-2012-302553 (2013).
36. Fletcher, S. P., et al. Intrahepatic Transcriptional Signature Associated with Response to Interferon-alpha Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS pathogens 11, e1005103, doi: 10.1371/journal.ppat.1005103 (2015).
37. Protzer, U., Maini, M. K., Knolle, P. A. Living in the liver: Hepatic infections. Nature reviews. Immunology 12, 201-213, doi: 10.1038/nri3169 (2012).
38. Nan, Y., et al. Hepatitis E virus inhibits type I interferon induction by ORF1 products. Journal of virology 88, 11924-11932, doi: 10.1128/JVI.01935-14 (2014).
39. Tateno, C., et al. Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Laboratory investigation; a journal of technical methods and pathology 93, 54-71, doi: 10.1038/labinvest.2012.158 (2013).
40. Tournoy, K. G., Depraetere, S., Meuleman, P., Leroux-Roels, G., Pauwels, R. A. Murine IL-2 receptor beta chain blockade improves human leukocyte engraftment in SCID mice. European journal of immunology 28, 3221-3230, doi:10.1002/(SICI)1521-4141(199810)28:10&60;3221::AID-IMMU3221&62;3.0.CO;2-S (1998).
41. Yu, C., et al. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: Similarities and differences. Journal of virology 84, 11264-11278, doi: 10.1128/JVI.01205-10 (2010).
42. Evans, D. T., Serra-Moreno, R., Singh, R. K., Guatelli, J. C. BST-2/tetherin: A new component of the innate immune response to enveloped viruses. Trends in microbiology 18, 388-396, doi: 10.1016/j.tim.2010.06.010 (2010).
43. Suneetha, P. V., et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 55, 695-708, doi: 10.1002/hep.24738 (2012).
44. Brown, A., et al. Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus. Hepatology 64, 1934-1950, doi: 10.1002/hep.28819 (2016).
45. Suemizu, H., et al. Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochemical and biophysical research communications 377, 248-252, doi: 10.1016/j.bbrc.2008.09.124 (2008).
46. Vanwolleghem, T., et al. Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. Journal of hepatology 53, 468-476, doi: 10.1016/j.jhep.2010.03.024 (2010).
47. Tsarev, S. A., et al. Characterization of a prototype strain of hepatitis E virus. Proceedings of the National Academy of Sciences of the United States of America 89, 559-563 (1992).
48. Pas, S. D., Fries, E., De Man, R. A., Osterhaus, A. D., Niesters, H. G. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 38, 2897-2901 (2000).
49. Pas, S. D., Niesters, H. G. Detection of HBV DNA using real time analysis. Journal of clinical virology: The official publication of the Pan American Society for Clinical Virology 25, 93-94 doi:S1386653202000161 [pii] (2002).
50. Movita, D., et al. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. Journal of virology 89, 4809-4817, doi: 10.1128/JVI.03733-14 (2015).
51. Vande Garde, M. D., et al. Liver Monocytes and Kupffer Cells Remain Transcriptionally Distinct during Chronic Viral Infection. PloS one 11, e0166094, doi: 10.1371/journal.pone.0166094 (2016).